Kineret®: Efficacy and safety in daily clinical practice: An interim analysis of the Kineret® response assessment initiative (kreative) protocol

International Journal of Clinical Pharmacology Research

Volumn 23, Issue 4, 2003, Pages 119-128

  Langer, Hans Eckhard ^a,c   Missler Karger, B ^b  

^a Evangelic Hospital   (Germany)

^b Department of Rheumatology ^*  (Germany)

^c Children s Hospital   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 1; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; TUMOR NECROSIS FACTOR ALPHA; ANTIRHEUMATIC AGENT; IL1RN PROTEIN, HUMAN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; METHOTREXATE; SIALOGLYCOPROTEIN;

ADULT; ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEADACHE; HUMAN; IMMUNOTHERAPY; INJECTION SITE; MAJOR CLINICAL STUDY; MALE; OPPORTUNISTIC INFECTION; RHEUMATOID ARTHRITIS; SIDE EFFECT; SKIN DISEASE; TUBERCULOSIS; DRUG ANTAGONISM; METHODOLOGY; MIDDLE AGED; POSTMARKETING SURVEILLANCE;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CLINICAL TRIALS; FEMALE; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; MALE; METHOTREXATE; MIDDLE AGED; PRODUCT SURVEILLANCE, POSTMARKETING; SIALOGLYCOPROTEINS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 3042548829     PISSN: 02511649     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Choy E., Panayi G. Cytokine pathways and joint inflammation in rheumatoid arthritis. New Engl. J. Med., 344(12), 907, 2001.
2. Firestein G.S., Boyle D.L., Yu C., et al. Synovial interleukin-1 receptor antagonist and interleukin-1 balance in rheumatoid arthritis. Arthritis Rheum., 37(5), 644, 1994.
3. Arend W.P. Interleukin-1 receptor antagonist. Adv. Immunol., 54, 167, 1993.
4. Bresnihan B., Alvaro-Gracia J., Cobby M., et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum., 41(12), 2196, 1998.
5. Cohen S., Hurd E., Cush J., et al. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: Results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum., 46(3), 614, 2002.
6. Nuki G., Bresnihan B., Bear M.B., McCabe D. Long-term safety and maintenance of clinical improvement following treatment with anakinra in patients with rheumatoid arthritis: Extension phase of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum., 46(11), 2838, 2002.
7. Jiang Y., Genant H.K., Watt I., et al. A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: Radiologic progression and correlation of Genant and Larsen scores. Arthritis Rheum., 43(5), 1001, 2000.
8. Shergy W.J., Cohen S.B., Greenwald M.W., et al. Anakinra (Kineret) inhibits the progression of radiographically measured joint destruction in rheumatoid arthritis. Ann. Rheum. Dis., 62(Suppl. 1), 192, 2003.
9. Roy M., Fleischmann R.M., Schechtman J., Bennett R. et al. Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis. A large, international, multicenter, placebo-controlled trial. Arthritis Rheum., 48(4), 927, 2003.
10. Van der Heijde D.M., van't Hof M., van Riel P.L., van der Putte L.B. Development of a disease activity score based on judgment of clinical practice by rheumatologists. J. Rheumatol., 20, 579, 1993.
11. Van Gestel A.M., Prevoo M.L.L., van't Hof M.A., et al. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Arthritis Rheum., 39(1), 34, 1996.